

1 A SARS-CoV-2 Nucleocapsid Variant that Affects Antigen Test Performance

2

3 Lori Bourassa^{a*}, Garrett A. Perchetti^{a*}, Quynh Phung^a, Michelle J. Lin^a, Margaret G. Mills^a,

4 Pavitra Roychoudhury^{a,b}, Kimberly G. Harmon^c, Jonathan C. Reed^a, Alexander L. Greninger^{a,b#}

5

6 ^aDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle,

7 Washington, USA

8 ^bViral and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA

9 ^cDepartment of Family Medicine, for Stanley Herring Department of Physical Medicine and

10 Rehabilitation, University of Washington, Seattle, Washington, USA

11

12 *Contributed Equally

13

14 #Corresponding Author, agrening@uw.edu

15

16 **Keywords:** SARS-CoV-2, antigen, Sofia 2, Quidel, false negative, variant, nucleocapsid

17

18

19

20 **Abstract**

21 More than one year into a global pandemic, SARS-CoV-2 is now defined by a variety of rapidly
22 evolving variant lineages. Several FDA authorized molecular diagnostic tests have been
23 impacted by viral variation, while no reports of viral variation affecting antigen test performance
24 have occurred to date. While determining the analytical sensitivity of the Quidel Sofia SARS
25 Antigen FIA test (Sofia 2), we uncovered a high viral load specimen that
26 repeatedly tested negative by this antigen test. Whole genome sequencing of the specimen
27 uncovered two mutations, T205I and D399N, present in the nucleocapsid protein of the
28 isolate. All six SARS-CoV-2 positive clinical specimens available in our laboratory with a D399N
29 nucleocapsid mutation and $C_T < 31$ were not detected by the Sofia 2 but detected by the
30 Abbott BinaxNOW COVID-19 Ag Card, while clinical specimens with the T205I mutation were
31 detected by both assays. Testing of recombinant SARS-CoV-2 nucleocapsid with these variants
32 demonstrated an approximate 1000-fold loss in sensitivity for the Quidel Sofia SARS Antigen
33 FIA test associated with the D399N mutation, while the BinaxNOW and Quidel Quickvue SARS
34 Antigen tests were unaffected by the mutation. The D399N nucleocapsid mutation has been
35 relatively uncommon to date, appearing in only 0.02% of genomes worldwide at time of
36 writing. Our results demonstrate how routine pathogen genomics can be integrated into the
37 clinical microbiology laboratory to investigate diagnostic edge cases, as well as the importance
38 of profiling antigenic diversity outside of the spike protein for SARS-CoV-2 diagnostics.

39

40

41 **Introduction**

42 The second year of the SARS-CoV-2 pandemic has been marked by the emergence of a
43 variety of lineages of the virus, several of which are associated with increased transmissibility
44 and immune escape. These variants are generally marked by mutations in the spike protein,
45 which undergoes the most rapid evolution in the coronaviruses due the continual need to
46 escape humoral immunity (1–4). The effect of viral evolution has affected every aspect of the
47 pandemic, from concerns over increased mortality to changes in therapeutic and vaccine
48 efficacy and diagnostic assay performance (5, 6).

49 To date, the FDA has noted four molecular tests whose performance could be altered by
50 SARS-CoV-2 evolution (7). Most famously, S gene target failures in the Thermo TaqPath assay
51 mark an N-terminal domain deletion in the spike protein that helps define the B.1.1.7 lineage
52 currently increasing in prevalence across the United States (8). Unlike molecular testing, the
53 effect of SARS-CoV-2 variants on antigen testing is not well understood. No variant affecting
54 antigen test performance has been described to date. Most SARS-CoV-2 antigen tests target
55 the nucleocapsid protein since it is stably associated with the RNA in the virion and present at
56 higher copy number than other viral structural proteins such as spike (9). Most evolutionary
57 analyses in coronavirus have focused on spike protein, since it is responsible for receptor
58 binding and entry and thus a constant target of neutralizing antibodies (4, 10). However, with
59 more than 18 months of spread in humans, a number of coding changes have been found in the
60 nucleocapsid protein (11). Here, we describe the characterization of an uncommon
61 nucleocapsid variant that affects the performance of the Quidel Sofia SARS Antigen FIA antigen
62 test run on the Sofia 2 platform.

63

64 **Materials and Methods**

65 *Specimens and study design*

66 Deidentified, residual patient nasopharyngeal (NP) samples submitted to the University of
67 Washington Virology Laboratory, Seattle, WA for clinical diagnostic testing were used in this
68 study. To minimize potential impact of different viral transport media on assay performance, only
69 clinical samples collected in phosphate-buffered saline (PBS) were used for analytical sensitivity
70 determination. This study was approved by the University of Washington Institutional Review
71 Board.

72

73 *Quidel Sofia 2 analytical sensitivity determination and confirmation*

74 To determine the limit of detection, we created a pooled positive specimen by equally mixing
75 three residual nasopharyngeal (NP) samples collected in PBS with C_T s of 23.7, 16.8 and 17.6
76 by a CDC-based laboratory developed test (12, 13). The pooled specimen was quantified using
77 two methodologies: reverse transcription-droplet digital PCR (RT-ddPCR, Bio-Rad, Hercules,
78 CA, USA) and qRT-PCR with the SARS-CoV-2 assay on the cobas 6800 (Roche, Basel,
79 Switzerland) as previously described (14).

80

81 Serial 10-fold dilutions of the neat pooled positive sample were run in triplicate on the Sofia 2
82 antigen test. 50 μ L of each dilution was applied to sterile swabs provided with the Sofia 2 kit
83 to simulate sample collection from the nares (15). The Quidel Reagent Solution was added to a
84 reagent tube and the nasal swab was mixed with the kit reagents by rolling the swab several
85 times and pressing the swab against the bottom of the tube as recommended by the
86 manufacturer. After incubating for 1 minute at room temperature, approximately 120 μ L of the
87 sample was pipetted into the test cassette. Each cassette was allowed to develop for 15
88 minutes and was read using the Sofia 2 instrument.

89

90 In addition to the pooled specimen, 58 deidentified residual NP samples collected in PBS that
91 previously tested positive for SARS-CoV-2 on the Roche cobas 6800 with a E-gene C_T range

92 14.27-37.97 were tested on the Sofia 2 SARS Antigen FIA following the methods described
93 above.

94

95 *Clinical specimen testing on Abbott BinaxNOW*

96 Testing of clinical specimens with the Abbott BinaxNOW COVID-19 Ag Card was performed as
97 described previously (15). Briefly, swabs provided with the kit were spiked with 50 μ L of clinical
98 nasal specimens previously collected into 3mL of PBS (16). The spiked swab specimen was
99 tested following the manufacturer's instructions.

100

101 *Quantitative RT-PCR and viral load determination of clinical specimens*

102 Viral load was determined by testing on the Roche cobas 6800 using the Seracare AccuPlex
103 SARS-CoV-2 Verification Panel standards. SARS-CoV-2 E-gene calibrators of 1e3 (C_T 33.41),
104 1e4 (C_T 30.71), and 1e5 copies (C_T 27.43) were used to calculate -0.33 slope and 14.17
105 intercept from the Roche cobas 6800 platform. Copies per swab were calculated by dividing the
106 copies/mL by 20, based on the 50 μ L of sample liquid used for rapid test.

107

108 *Whole genome sequencing and genome mining*

109 SARS-CoV-2 whole genome sequencing was performed using the Swift Biosciences v2 or
110 Illumina COVID-Seq amplicon tiling platforms as described previously (17). To determine
111 descriptive epidemiology of the nucleocapsid D399N mutation, SARS-CoV-2 whole genomes
112 were downloaded from GISAID on April 18, 2021 (18). Figures were generated with custom R
113 code (github.com/greninger-lab/sars_cov2_antigen_test_n_gene), using ggplot (18), UpSetR
114 (19), and PANGO lineages (20).

115

116 *Cloning of SARS-CoV-2 N gene wild-type and mutants*

117 The ORF encoding N wild-type was amplified from a plasmid encoding N sequence based on
118 NC_045512.2 (a gift from Michael Gale Jr lab) using the COVID-N-C-Strep-F and COVID-N-C-
119 Strep-R primers. To obtain the ORF encoding N T205I/D399N, RNA was extracted from a
120 previously sequenced clinical SARS-CoV-2 isolate that encodes the T205I/D399N mutations in
121 N (WA-UW-62718; EPI_ISL_1366195) and converted to cDNA using Superscript IV
122 (ThermoFisher Scientific, Waltham, MA, USA) with COVID-N-C-Strep-R primer followed by
123 PCR utilizing the same primer pair that amplified N wild-type gene. The N wild-type or N
124 T205I/D399N amplicons were then cloned into a modified pcDNA4/TO vector with a C-terminal
125 2x Strep-Tag II using the In-Fusion HD cloning kit (Takara Bio, Kusatsu, Shiga, Japan). To
126 obtain the construct encoding the N T205I amino acid change an amplicon encoding the first
127 half of the N gene encoding T205I (made by PCR using primers COVID-N-C-Strep-F and
128 COVID N nt864R with the N T205I/D399N cDNA template) and an amplicon encoding the
129 second half of the N wild-type gene (made by PCR using primers COVID N nt864R and COVID-
130 N-C-Strep-R with the N wild-type plasmid template), were cloned into the modified pcDNA4/TO
131 vector with a C-terminal 2x Strep-Tag II using the In-Fusion HD cloning kit (Takara). The N
132 D399N construct was made following the same strategy except by combining an amplicon
133 encoding the first half of the N wild-type gene (made by PCR using primers COVID-N-C-Strep-F
134 and COVID N nt864R with the N wild-type plasmid) and an amplicon encoding the second half
135 of the N gene encoding D399N (made by PCR using primers COVID N nt864R and COVID-N-
136 C-Strep-R with the N T205I/D399N cDNA template). The sequence of all plasmids was
137 confirmed by Sanger sequencing (Genewiz, Inc.) and all primers are listed in Table S1. All PCR
138 reactions were performed with CloneAmp Hi-Fi PCR premix (Takara).

139

140 *Cell culture, transfection, and cell lysis*

141 293T cells were maintained in Dulbecco's modified Eagle medium (DMEM) high glucose with
142 10% fetal bovine serum (FBS), 10 mM HEPES, penicillin and streptomycin. Cells were

143 transfected with 1 μg of plasmid DNA using 3:1 ratio of PEI MAX (Polysciences, Inc.
144 Warrington, PA, USA) in Opti-MEM. Cells were harvested 48 h after transfection by washing
145 cells with PBS (with Ca^{2+} and Mg^{2+}) followed by lysis in 1xLSM lysis buffer (20 mM HEPES pH
146 7.9, 14 mM KAc, 1 mM NaCl, 1 mM MgAcetate₂, 0.3% NP40) with 1% protease inhibitor cocktail
147 (Sigma-Aldrich, St. Louis, MO, USA). Cell lysates were clarified by centrifugation at 200xg for 10
148 min at 4°C, followed by a second clarification by centrifugation at 21,100g for 1 min at 4°C.
149 Lysates were then stored at -80°C prior to analysis.

150

151 *Confirming SARS-CoV-2 N expression and estimating concentration of SARS-CoV-2 N in*
152 *lysates*

153 Total protein in 293T cell lysates was measured using the Pierce BCA protein assay kit
154 (ThermoFisher) and the samples were normalized to 125 $\mu\text{g}/\text{mL}$ in sample buffer. To estimate
155 the concentration of N in cell lysates a titration of recombinant his-tagged N protein
156 (ThermoFisher) was prepared ranging from 62.5 ng to 250 ng in sample buffer. Lysates
157 (1.25 μg per lane) and the titration of recombinant his-tagged N (ThermoFisher) were run on a
158 4-12% Bis-Tris sodium dodecyl sulfate (SDS)-polyacrylamide gel with
159 morpholinepropanesulfonic acid (MOPS) running buffer (Invitrogen, Carlsbad, CA, USA) under
160 reducing conditions. The samples were then transferred to a 0.45- μm nitrocellulose membrane
161 using the XCell Blot II module (Invitrogen). Blotting was performed with 1:500 anti-SARS-CoV-2
162 Nucleocapsid Protein (E8R1L) mouse IgG_{2a} monoclonal antibody (Cell Signaling Technology,
163 Danvers, MA, USA) followed by staining with 1:2,000 IRDye 800CW anti-mouse IgG secondary
164 antibody (Li-Cor Biosciences, Lincoln, NE, USA). Blots were scanned on Sapphire
165 Biomolecular Imager (Azure Biosystems, Dublin, CA, USA) and quantified using Image Studio
166 Lite version 5.2.5 (Li-Cor).

167

168 To estimate the concentration of N in the lysate, the estimated nanograms of N quantified by
169 western blot was divided by 10 to account for loading volume and then multiplied by dilution
170 factor required to bring the lysates to 0.125 mg/mL (lysates were diluted 22.4-fold, 25.6-fold,
171 21.6-fold, and 28-fold for N WT, N T205I, N D399N, and N T205I/D399N, respectively). This
172 resulted in a concentration of 336.2 ng/ μ L, 189.7 ng/ μ L, 403.9 ng/ μ L, 244.2 ng/ μ L for N WT, N
173 T205I, N D399N, and N T205I/D399N, respectively. These values were used to calculate pg
174 quantity of N going into the 1:10 dilution for N variant based on absorbing 50 μ L diluted lysate
175 for each antigen test.

176

177 *Abbott BinaxNOW, Quidel Sofia 2, and Quidel QuickVue testing of cell lysates.*

178 Lysates from 293T cells transfected with N wildtype, N T205I, N D399N, N T205I/D399N, or
179 pcDNA4/TO vector were kept frozen at -80°C prior to use in antigen testing. Lysates were
180 thawed and diluted in 1xLSM lysis buffer at the indicated ten-fold dilutions (from neat to 1:10⁶).
181 Subsequent dilutions tested between 10-fold dilutions were either serially diluted from existing
182 10-fold dilutions or a new 10-fold dilution was made and retested. For each test, 50 μ L of
183 sample was transferred to 1.5 mL microcentrifuge tube and the material was absorbed to a kit
184 specific swab. The swab was tested following the manufacturer's instructions. BinaxNOW and
185 Quidel QuickVue SARS Antigen Test results were independently evaluated by two individuals,
186 and specimens were called negative if disagreement, inclusive of the 1:100,000 T205I
187 BinaxNow, 1:100,000 WT QuickVue, 1:100,000 D399N QuickVue specimens.

188

189 **Results**

190 *Quidel Sofia SARS Antigen FIA analytical sensitivity is approximately 54,900 copies/mL*

191 To determine the analytical sensitivity of the Sofia SARS Antigen FIA on the Sofia 2 analyzer
192 (referred to here as the Sofia 2 test), a stock pooled positive sample was determined to have a
193 viral load of 8.66x10⁶ copies/mL by the Roche cobas SARS-CoV-2 assay and

194 1.10×10^7 copies/mL by RT-ddPCR. Using ten-fold serial dilutions of the pooled sample tested in
195 triplicate, the initial limit of detection (LoD) was determined to be between 1:10 and 1:100 (Table
196 1). Twenty additional 1:10 dilutions were tested to confirm the LoD. However, only 12/20 (60%)
197 specimens of the 1:10 dilution were detected by the assay. Therefore, 1:9 dilutions were tested,
198 with 20/20 (100%) samples detected. Quantification of the 1:9 dilution by the Roche cobas 6800
199 and RT-ddPCR estimated the Sofia 2 SARS Antigen FIA LoD between 9.62×10^5 and
200 1.22×10^6 virus copies/mL, respectively. To account for the lower sample volume used by the
201 rapid antigen test compared to RT-PCR platforms (50 μ L compared to 200-500 μ L used by
202 commercial RT-PCR platforms) a copies/swab and theoretical C_T calculation for
203 the 50 μ L volume absorbed on the swab was included to better represent the LoD of the antigen
204 test. The LoD of the Sofia 2 SARS antigen FIA was determined at 4.81×10^4 and 6.11×10^4 virus
205 copies/swab by cobas 6800 and RT-ddPCR, respectively, or an approximate theoretical qRT-
206 PCR C_T of 29.

207 To determine whether this analytical sensitivity was reflected in a broader set of
208 specimens, we performed antigen testing on 58 deidentified residual NP swabs collected for
209 clinical diagnostic testing that comprised a wide range of viral loads (C_T 14.27-37.97). Of the 23
210 samples included within the LoD established using the pooled specimen, 22/23 (95.7%) were
211 detected by rapid testing. Three samples below the LoD (2.25×10^4 , 1.24×10^4 , 4.66×10^3
212 copies/swab) were detected but none beyond 4,660 virus copies/swab (0/30), corresponding to
213 a theoretical cobas 6800 C_T of 32.9, were detected (Figure 1, Table 2).

214

215 *Clinical specimens with nucleocapsid T205I/D399N mutation repeatedly test negative on Quidel*
216 *Sofia 2 antigen test*

217 Although the number of positive detections from blinded SARS-CoV-2 samples within
218 the established LoD was >95%, one sample with a viral load of 213,000 copies/swab – far
219 exceeding the estimated LoD of 48,100-61,100 copies/swab – tested negative on the Quidel

220 Sofia 2. The sample remained negative upon repeat testing on the platform. This sample was
221 re-quantified on a separate molecular platform, the Panther Fusion (Hologic, Marlborough, MA,
222 USA), and was confirmed to contain approximately 2×10^5 virus copies/swab.

223 Because of the concern for variants on determining diagnostic assay performance, we
224 performed SARS-CoV-2 whole genome sequencing on this unexpectedly negative specimen.
225 Whole genome sequencing revealed two coding mutations in the N gene, T205I and
226 D399N. Both mutations are located in areas of the 419 aa protein without an available structure,
227 with the T205I in the serine-arginine rich region and the D399N in the far C-terminus (21, 22). Of
228 the 1,144,036 GISAID consensus sequences available as of April 18, 2021, we found 222
229 sequences with the D399N mutation, for a global prevalence of only 0.019%. This mutation is
230 found mostly in the United States ($n=125$, 56.3% of total D399N variants), and most commonly
231 in the background of the B.1.429 / 20C clade ($n=63$) (Figure 2A/B). We further analyzed D399N
232 in the context of other N gene mutations (Figure 3). D399N rarely emerges alone as a single
233 variant in the N gene ($n=11$, 5.0%), and most frequently appears with only T205I ($n=78$, 35.1%).
234 T205I is a common N gene mutation in global consensus sequences, at 42.9% prevalence,
235 making the co-occurrence of D399N and T205I a relatively rare event at only 0.16% of total
236 T205I mutations.

237 Upon review of specimens previously sequenced in our lab, we found an additional 6
238 specimens that contained the same two nucleocapsid mutations and were available for further
239 testing. While 4/6 samples were within the LoD of the Sofia antigen FIA established here, 0/6
240 samples were detected by the assay. Five of the 6 samples harboring the two N gene mutations
241 were detected on a second antigen test, the Abbott BinaxNOW COVID-19 card. The sixth
242 sample was determined to have a theoretical C_T of 37.6, far exceeding the analytical
243 sensitivity of the Abbott BinaxNOW COVID-19, which was previously determined to be an
244 approximate C_T of 29-30 (15).

245

246 *Ectopically expressed nucleocapsid protein containing the D399N mutation results in a*
247 *~1000-fold reduction in analytical sensitivity specifically on the Quidel Sofia SARS Antigen FIA*
248 *test*

249 Testing of available clinical samples showed that the Quidel Sofia 2 antigen test has
250 reduced sensitivity for specimens associated with the N T205I/D399N variant, but not for
251 specimens associated with the N T205I variant. Given that the N D399N mutation rarely
252 emerges alone, no clinical specimens were available for antigen testing to directly address
253 whether D399N mutation is solely responsible for the reduced sensitivity of the Quidel Sofia 2
254 antigen test. To evaluate the role of the D399N mutation alone or in combination with T205I, we
255 transiently expressed N variants in 293T cells and subjected lysates from these 293T cells to
256 antigen testing.

257 The N wildtype gene from Wuhan-Hu-1 (N WT) and N gene variants N T205I, N D399N,
258 and N T205I/D399N were each cloned into a CMV expression vector with a C-terminal 2XStrep-
259 Tag II. Each of these constructs and the empty vector were transfected into 293T cells and
260 lysates were harvested 48 h post-transfection. Western blot analysis with anti-N of cell lysates
261 and a commercial recombinant N standard was performed to confirm the expression of all
262 recombinant N proteins and to estimate the amount of N protein produced. Based on the
263 estimated nanograms of N loaded into the western blot, the concentration of N in each lysate
264 was estimated to vary from 190 ng/ μ L to 404 ng/ μ L (Figure 4).

265 Next, we wanted to compare the analytical sensitivity of the Quidel Sofia 2 and the
266 Abbott BinaxNOW antigen test kits for the N variants expressed in 293T cells. We confirmed
267 that lysates from 293T cells transfected with the empty vector, which did not express N, were
268 not detected (Table 4). To compare the N variants, we first diluted the lysates that contained a
269 higher concentration of N protein by 3-fold and then each lysate was subjected to a 10-fold
270 serial dilution beginning at 1:10 and ending at 1:10⁶ to determine the limit of detection for each
271 antigen test. Based on the western blot quantification, the expected pg of N per swab from the

272 1:10 dilution is 5.6×10^5 pg, 9.5×10^5 pg, 6.7×10^5 pg, 12.2×10^5 pg for N WT, N T205I, N D399N,
273 and N T205I/D399N, respectively. In testing of clinical specimens, as described above, the
274 Abbott BinaxNOW test detected specimens associated with both N T205I and N T205I/D399N
275 variants with similar sensitivity. Likewise, the Abbott BinaxNOW kit detected each of these N
276 variants in 293T lysates with equivalent sensitivity down to the $1:10^5$ dilution (3/3 or 2/3 positive
277 tests), corresponding to approximately 95 pg of N205I and 122 pg of N T205I/D399N (Table 4).
278 Furthermore, the Abbott BinaxNOW test detected lysates that contain N with just the single
279 mutation D399N or N WT with sensitivity equivalent to the other N variants. Thus, the Abbott
280 BinaxNOW test appears unaffected by the N variants T205I, D399N, or T205/D399N.

281 In contrast to the Abbott BinaxNOW kit, the Quidel Sofia 2 antigen test exhibited
282 significantly lower sensitivity for clinical specimens associated with N T205I/D399N compared to
283 clinical specimens associated with N T205I. Testing of 293T lysates containing N T205I or N
284 T205I/D399N on the Quidel Sofia 2 antigen test confirmed this finding with the antigen test
285 exhibiting an approximately 1000-fold reduced sensitivity between lysates containing variants N
286 T205I versus N T205I/D399N, based on comparing the final dilution where all tests were
287 positive. This corresponded to a difference of approximately 948 pg N T205I and 1.22×10^6 pg
288 of N T205I/D399N (Table 4). In contrast, Quidel Sofia 2 antigen test has approximately
289 equivalent sensitivity between lysates containing N WT and N T205I since both were 100%
290 detected (3/3) at $1:10^4$ dilution or approximately 560 pg of N WT protein and 948 pg of N T205I
291 protein.

292 To determine if D399N alone is sufficient for the reduced sensitivity of the Quidel Sofia 2
293 antigen test, we next tested lysates that contain N D399N mutation alone. In contrast to lysates
294 containing N T205I alone or N WT, the sensitivity of the Quidel Sofia 2 antigen test for lysates
295 containing N D399N mutation alone was reduced by 1000-fold (comparing the last dilution
296 where all tests were positive), similar to lysates containing the N T205I/D399N double mutant.

297 (Table 4). These findings demonstrate that the N D399N mutation alone was sufficient to reduce
298 the sensitivity of the Quidel Sofia 2 antigen test significantly by 1000-fold.

299 We next tested the 293T lysates containing N variants on another point-of-care, rapid,
300 FDA authorized COVID-19 antigen test manufactured by Quidel Corporation, Quidel QuickVue,
301 to determine if the Quidel QuickVue kit sensitivity is affected by the N D399N mutation. The
302 QuickVue test is performed as a dipstick test and does not require a reader like the Sofia 2 test.
303 In contrast to our findings on the Quidel Sofia 2 antigen tests, no significant difference was
304 observed in sensitivity between any of the N variants, indicating that the Quidel QuickVue test is
305 not affected by the D399N mutation (Table 4).

306

307 **Discussion**

308 Here, we simultaneously determined the analytical sensitivity of the Quidel Sofia SARS
309 Antigen FIA run on the Sofia 2 analyzer and uncovered a nucleocapsid variant that dramatically
310 affects the analytical sensitivity of this antigen test. We found the analytical sensitivity of the
311 Quidel Sofia 2 corresponded to 48,100 – 61,100 copies/swab, which closely matches the
312 analytical sensitivity (40,400 – 80,600 copies/swab) we found for the Abbott BinaxNOW (15).
313 While not absolutely comparable, the relative analytical sensitivities agree with those listed in
314 the package inserts for the Quidel Sofia 2 and Abbott BinaxNOW assays of 113 TCID₅₀ units/mL
315 and 140.6 TCID₅₀ units/mL, respectively. Our limited testing against recombinant proteins hinted
316 at a slightly better analytical sensitivity for the Abbott BinaxNOW and Quickvue assays
317 compared to the Quidel Sofia SARS Antigen FIA. However, this testing was run against
318 comparatively few samples and mainly used to demonstrate the semi-quantitative effects of
319 nucleocapsid mutations on test performance.

320 We further characterized a single amino acid mutation (D399N) that affected the
321 analytical sensitivity of the Quidel Sofia SARS Antigen FIA by approximately 1000-fold, when
322 measured on the Sofia 2. The D399N mutation that affected the Quidel Sofia 2 assay

323 performance seems to be of limited public health importance at this time given the few number
324 of cases it has been detected in. It is also a mystery as to how this amino acid change could
325 affect nucleocapsid function. Of note, no complete SARS-CoV-2 nucleocapsid structures are
326 available, with only the N-terminal RNA-binding region and the C-terminal domain (21, 22).
327 Neither the T205I or D399N mutation recovered in our interrogated specimens occurred in these
328 regions, nor could high-confidence models be created for these regions in HHPred (23). Given
329 that one of these mutations affected diagnostic sensitivity, our data illustrate the comparable
330 lack of understanding of how mutations can affect coronavirus nucleocapsid protein as
331 compared to the spike protein.

332 Compared to molecular testing, antigen test performance is often less well-characterized
333 and the effect of viral variation on assay performance only compounds this issue. Antigen tests
334 are often performed in a distributed manner, away from the availability of comparator platforms
335 to monitor test performance. Antigen tests often make use of the entire specimen, obviating the
336 ability to run same sample comparisons on other platforms. And, while it is relatively easy to
337 understand how viral mutation could affect PCR primer binding – even if they are not routinely
338 publicly available for most FDA authorized platforms – antigen testing is often literally a black
339 box, with no public epitope mapping information or even knowledge of whether such data exists.
340 Increasingly, initiatives from the NIH, CDC, and FDA are trying to systematically examine the
341 effect of variants on diagnostic performance, but it is worth noting that multiple molecular tests
342 have already been found to be affected by variants while the first antigen test affected has not
343 been described until more than a year after authorization (24, 25).

344 The main limitations of the study include the small number of specimens tested, use of
345 specimens that do not follow the manufacturer’s recommended testing protocol, use of
346 unpurified recombinant protein lysates to confirm mutation effects, and limited testing to initial
347 determination of analytical sensitivity using recombinant protein. Nonetheless, we found
348 consistent results between use of clinical specimens and recombinant proteins that bulwarks

349 our results. The Quidel Sofia SARS Antigen FIA is a sandwich ELISA which involves both a
350 capture and detection antibody. At this time, it is not clear whether the D399N mutation alters
351 binding by the capture or the detection antibody. Without the antibodies used in these assays, it
352 is difficult to determine equilibrium dissociation constants, perform epitope mapping, or measure
353 other biochemical properties associated with the test reagents.

354 Our data further highlight the increasing returns of widespread genome sequencing in
355 the clinical microbiology community (26, 27). With routine SARS-CoV-2 whole genome
356 sequencing available in our lab, we were rapidly able to determine the coding mutations present
357 in a diagnostic edge case. This mutation could further be probed by examining more specimens
358 for which routine genome sequencing had been performed. All told, the work in the clinical
359 virology described here was completed in under four weeks and the antigen test manufacturer
360 was made aware within four days of our testing of the genotyped clinical specimens. Although
361 this specific story uncovered a variant that affected SARS-CoV-2 antigen testing, the ability of
362 decentralized, widespread, routine whole genome sequencing to uncover the genetic basis of
363 assay performance could equally be applied to almost any diagnostic test in the clinical
364 microbiology lab.

365

366

367 *Acknowledgements*

368 The authors thank the staff of UW Virology as well as financial support from the Chisholm
369 Foundation, and Quidel and Abbott for providing in-kind kits for testing. The funders had no role
370 in study design, data collection and interpretation, or the decision to submit the work for
371 publication. ALG reports contract testing from Abbott and research support from Merck and
372 Gilead. The authors also gratefully acknowledge authors from originating laboratories
373 responsible for obtaining the specimens and the submitting laboratories where genetic

374 sequence data were generated and shared via the GISAID Initiative, on which some of this

375 research is based.

376

377

378 **References**

- 379 1. Faria NR, Mellan TA, Whittaker C, Claro IM, Candido D da S, Mishra S, Crispim MAE, Sales
380 FCS, Hawryluk I, McCrone JT, Hulswit RJG, Franco LAM, Ramundo MS, de Jesus JG,
381 Andrade PS, Coletti TM, Ferreira GM, Silva CAM, Manuli ER, Pereira RHM, Peixoto PS,
382 Kraemer MUG, Gaburo N, Camilo C da C, Hoeltgebaum H, Souza WM, Rocha EC, de
383 Souza LM, de Pinho MC, Araujo LJT, Malta FSV, de Lima AB, Silva J do P, Zauli DAG,
384 Ferreira AC de S, Schnekenberg RP, Laydon DJ, Walker PGT, Schlüter HM, Dos Santos
385 ALP, Vidal MS, Del Caro VS, Filho RMF, Dos Santos HM, Aguiar RS, Proença-Modena JL,
386 Nelson B, Hay JA, Monod M, Miscouridou X, Coupland H, Sonabend R, Vollmer M, Gandy
387 A, Prete CA, Nascimento VH, Suchard MA, Bowden TA, Pond SLK, Wu C-H, Ratmann O,
388 Ferguson NM, Dye C, Loman NJ, Lemey P, Rambaut A, Fraiji NA, Carvalho M do PSS,
389 Pybus OG, Flaxman S, Bhatt S, Sabino EC. 2021. Genomics and epidemiology of the P.1
390 SARS-CoV-2 lineage in Manaus, Brazil. *Science* <https://doi.org/10.1126/science.abh2644>.
- 391 2. Tegally H, Wilkinson E, Lessells RJ, Giandhari J, Pillay S, Msomi N, Mlisana K, Bhiman JN,
392 von Gottberg A, Walaza S, Fonseca V, Allam M, Ismail A, Glass AJ, Engelbrecht S, Van Zyl
393 G, Preiser W, Williamson C, Petruccione F, Sigal A, Gazy I, Hardie D, Hsiao N-Y, Martin D,
394 York D, Goedhals D, San EJ, Giovanetti M, Lourenço J, Alcantara LCJ, de Oliveira T. 2021.
395 Sixteen novel lineages of SARS-CoV-2 in South Africa. *Nat Med* 27:440–446.
- 396 3. McCarthy KR, Rennick LJ, Nambulli S, Robinson-McCarthy LR, Bain WG, Haidar G, Duprex
397 WP. 2021. Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody
398 escape. *Science* 371:1139–1142.
- 399 4. Eguia RT, Crawford KHD, Stevens-Ayers T, Kelnhöfer-Millevolte L, Greninger AL, Englund
400 JA, Boeckh MJ, Bloom JD. 2021. A human coronavirus evolves antigenically to escape
401 antibody immunity. *PLoS Pathog* 17:e1009453.

- 402 5. Starr TN, Greaney AJ, Dingens AS, Bloom JD. 2021. Complete map of SARS-CoV-2 RBD
403 mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-
404 CoV016. *Cell Rep Med* 2:100255.
- 405 6. Davies NG, Jarvis CI, CMMID COVID-19 Working Group, Edmunds WJ, Jewell NP, Diaz-
406 Ordaz K, Keogh RH. 2021. Increased mortality in community-tested cases of SARS-CoV-2
407 lineage B.1.1.7. *Nature* <https://doi.org/10.1038/s41586-021-03426-1>.
- 408 7. Health C for D and R. 2021. SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests. FDA.
- 409 8. Kidd M, Richter A, Best A, Cumley N, Mirza J, Percival B, Mayhew M, Megram O, Ashford
410 F, White T, Moles-Garcia E, Crawford L, Bosworth A, Atabani SF, Plant T, McNally A. 2021.
411 S-variant SARS-CoV-2 lineage B1.1.7 is associated with significantly higher viral loads in
412 samples tested by ThermoFisher TaqPath RT-qPCR. *The Journal of Infectious Diseases*
413 <https://doi.org/10.1093/infdis/jiab082>.
- 414 9. Yao H, Song Y, Chen Y, Wu N, Xu J, Sun C, Zhang J, Weng T, Zhang Z, Wu Z, Cheng L,
415 Shi D, Lu X, Lei J, Crispin M, Shi Y, Li L, Li S. 2020. Molecular Architecture of the SARS-
416 CoV-2 Virus. *Cell* 183:730-738.e13.
- 417 10. Kistler KE, Bedford T. 2021. Evidence for adaptive evolution in the receptor-binding domain
418 of seasonal coronaviruses OC43 and 229e. *eLife* 10:e64509.
- 419 11. Troyano-Hernández P, Reinoso R, Holguín Á. 2021. Evolution of SARS-CoV-2 Envelope,
420 Membrane, Nucleocapsid, and Spike Structural Proteins from the Beginning of the
421 Pandemic to September 2020: A Global and Regional Approach by Epidemiological Week.
422 *Viruses* 13.

- 423 12. Nalla AK, Casto AM, Huang M-LW, Perchetti GA, Sampoleo R, Shrestha L, Wei Y, Zhu H,
424 Jerome KR, Greninger AL. 2020. Comparative Performance of SARS-CoV-2 Detection
425 Assays using Seven Different Primer/Probe Sets and One Assay Kit. J Clin Microbiol
426 <https://doi.org/10.1128/JCM.00557-20>.
- 427 13. Lieberman JA, Pepper G, Naccache SN, Huang M-L, Jerome KR, Greninger AL. 2020.
428 Comparison of Commercially Available and Laboratory Developed Assays for in vitro
429 Detection of SARS-CoV-2 in Clinical Laboratories. J Clin Microbiol
430 <https://doi.org/10.1128/JCM.00821-20>.
- 431 14. Perchetti GA, Nalla AK, Huang M-L, Zhu H, Wei Y, Stensland L, Loprieno MA, Jerome KR,
432 Greninger AL. 2020. Validation of SARS-CoV-2 detection across multiple specimen types. J
433 Clin Virol 128:104438.
- 434 15. Perchetti GA, Huang M-L, Mills MG, Jerome KR, Greninger AL. 2020. Analytical Sensitivity
435 of the Abbott BinaxNOW COVID-19 Ag CARD. J Clin Microbiol
436 <https://doi.org/10.1128/JCM.02880-20>.
- 437 16. Perchetti GA, Huang M-L, Peddu V, Jerome KR, Greninger AL. 2020. Stability of SARS-
438 CoV-2 in Phosphate-Buffered Saline for Molecular Detection. J Clin Microbiol 58.
- 439 17. Addetia A, Lin MJ, Peddu V, Roychoudhury P, Jerome KR, Greninger AL. 2020. Sensitive
440 Recovery of Complete SARS-CoV-2 Genomes from Clinical Samples by Use of Swift
441 Biosciences' SARS-CoV-2 Multiplex Amplicon Sequencing Panel. J Clin Microbiol 59.
- 442 18. Shu Y, McCauley J. 2017. GISAID: Global initiative on sharing all influenza data – from
443 vision to reality. Euro Surveill 22.
- 444 19. Wickham H. 2016. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York.

- 445 20. Conway JR, Lex A, Gehlenborg N. 2017. UpSetR: an R package for the visualization of
446 intersecting sets and their properties. *Bioinformatics* 33:2938–2940.
- 447 21. Kang S, Yang M, Hong Z, Zhang L, Huang Z, Chen X, He S, Zhou Z, Zhou Z, Chen Q, Yan
448 Y, Zhang C, Shan H, Chen S. 2020. Crystal structure of SARS-CoV-2 nucleocapsid protein
449 RNA binding domain reveals potential unique drug targeting sites. *Acta Pharm Sin B*
450 10:1228–1238.
- 451 22. Yang M, He S, Chen X, Huang Z, Zhou Z, Zhou Z, Chen Q, Chen S, Kang S. 2020.
452 Structural Insight Into the SARS-CoV-2 Nucleocapsid Protein C-Terminal Domain Reveals a
453 Novel Recognition Mechanism for Viral Transcriptional Regulatory Sequences. *Front Chem*
454 8:624765.
- 455 23. Söding J, Biegert A, Lupas AN. 2005. The HHpred interactive server for protein homology
456 detection and structure prediction. *Nucleic Acids Res* 33:W244-248.
- 457 24. Casto AM, Huang M-LW, Xie H, Jerome KR, Wald A, Johnston CM, Greninger AL. 2020.
458 Herpes Simplex Virus Mistyping due to HSV-1 × HSV-2 Interspecies Recombination in Viral
459 Gene Encoding Glycoprotein B. *Viruses* 12.
- 460 25. Greninger AL. 2019. Societal Implications of the Internet of Pathogens. *J Clin Microbiol* 57.

461

462

463 **Figure Legends:**

464 **Figure 1.** Confirmation of analytical sensitivity of the using clinical specimens. Specimens are
465 depicted in descending order by copies/swab from left to right. Specimens depicted with purple
466 circles were detected by the Quidel Sofia 2 while gold circles were undetected. The analytical
467 sensitivity determined using dilutions of a pooled positive of 54,900 copies/swab is denoted by
468 the dotted line. The arrow denotes the specimen that was negative on repeat testing and
469 subjected to whole genome sequencing.

470
471 **Figure 2.** Prevalence of D399N mutations in deposited GISAID consensus sequences. A)
472 Distribution of deposited GISAID genomes with the D399N mutation across the globe. Each dot
473 represents sequences in a GISAID-defined subregion, with area of the dot proportional to the
474 number of sequences. Dots are colored by PANGO lineage. B) Distribution of deposited GISAID
475 genomes with the D399N mutation over time. Countries and subregions are indicated on the
476 left. Each dot represents a unique deposited sequence, colored by PANGO lineage.

477
478 **Figure 3.** D399N in the context of other N gene mutations in deposited GISAID consensus
479 sequences. Matrix shows co-occurrences of D399N with other N gene mutations, sorted in
480 descending frequency from left to right, with frequencies plotted above as a bar plot. Frequency
481 of each individual mutation is plotted to the left. Highlighted in orange are the genomes with
482 D399N without any co-occurring N gene mutations. N gene mutations with <10 total co-
483 occurrences are collapsed into an “Other N mutations” category.

484
485 **Figure 4.** Western blot quantitation of ectopically expressed recombinant SARS-CoV-2
486 nucleocapsid protein in 293T cells. To evaluate N protein expression, total protein normalized
487 lysates from 293T cells transfected with N Wuhan-Hu-1 (WT), N T205I, N D399N, N
488 T205I/D399M, or empty vector and either 250 ng, 125 ng, or 62.5 ng of recombinant N were

489 subjected to SDS-PAGE followed by α N western blot. The estimated nanograms of N loaded
490 per lane for each variant is shown beneath the western blot determined from a standard curve
491 generated by quantification of the commercial recombinant N standards.

492

493

Tables

Table 1. Analytical sensitivity of Quidel SARS Antigen FIA test using dilution of a pooled positive

Sample Dilution	Initial Replicates Detected	Initial % Positive	Confirmatory Replicates Detected	Copies/mL (ddPCR)	Copies/swab (ddPCR)	Copies/mL (Cobas 6800)	Copies/swab (Cobas 6800)
Neat	3/3	100%		1.10E+07	5.50E+05	8.66E+06	1.73E+05
1:9	3/3	100%	20/20	1.22E+06	6.11E+04	9.62E+05	4.81E+04
1:10	3/3	100%	12/20	1.10E+06	5.50E+04	8.66E+05	4.33E+04
1:20	0/3	0%		5.50E+05	2.75E+04	4.33E+05	8.66E+03
1:30	0/3	0%		3.67E+05	1.83E+04	2.89E+05	5.77E+03
1:40	0/3	0%		2.75E+05	1.38E+04	2.16E+05	4.33E+03
1:50	0/3	0%		2.20E+05	1.10E+04	1.73E+05	3.46E+03
1:100	0/3	0%		1.10E+05	5.50E+03	8.66E+04	1.73E+03
1:1,000	0/3	0%		1.10E+04	5.50E+02	8.66E+03	4.81E+01
1:10,000	0/3	0%		1.10E+03	5.50E+01	8.66E+02	4.33E+01
1:100,000	0/3	0%		1.10E+02	5.50E+00	8.66E+01	8.66E+00
Pos Control	6/6	100%					
Neg Control	0/6	0%					

Table 2. Confirmation of Analytical Sensitivity of Quidel SARS Antigen FIA test on Sofia 2 analyzer using clinical specimens. Clinical specimens in PBS transport media were spiked onto swabs for antigen test, resulting in a calculated theoretical C_T value of how much virus was used as input for the antigen test.

UW Sample ID	Original Roche cobas C_T	Original Copies / mL	Copies / swab	Theoretical Roche cobas C_T	Quidel SOFIA 2 Antigen Detection
PBS 21	14.24	2.67E+09	1.34E+08	19.6	Positive
PBS 10	14.49	2.20E+09	1.10E+08	19.9	Positive
PBS 2	15.12	1.36E+09	6.80E+07	20.5	Positive
PBS 7	17.23	2.69E+08	1.35E+07	22.6	Positive
PBS 33	17.41	2.34E+08	1.17E+07	22.8	Positive
PBS 35	19.18	6.02E+07	3.01E+06	24.5	Positive
PBS 32	19.19	5.98E+07	2.99E+06	24.5	Positive
PBS 29	19.35	5.28E+07	2.64E+06	24.7	Positive
PBS 38	19.8	3.74E+07	1.87E+06	25.2	Positive
PBS 55	20.38	2.40E+07	1.20E+06	25.7	Positive
PBS 15	20.5	2.19E+07	1.09E+06	25.8	Positive
PBS 37	20.52	2.15E+07	1.08E+06	25.9	Positive
PBS 53	21.01	1.48E+07	7.39E+05	26.4	Positive
PBS 14	21.29	1.19E+07	5.96E+05	26.6	Positive
PBS 45	21.3	1.18E+07	5.91E+05	26.6	Positive
PBS 19	21.56	9.69E+06	4.84E+05	26.9	Positive
PBS 52	21.58	9.54E+06	4.77E+05	26.9	Positive
PBS 22	21.63	9.18E+06	4.59E+05	27.0	Positive
PBS 26	22.52	4.64E+06	2.32E+05	27.9	Positive
PBS 36	22.63	4.26E+06	2.13E+05	28.0	Negative
PBS 34	22.66	4.16E+06	2.08E+05	28.0	Positive
PBS 51	23.23	2.69E+06	1.34E+05	28.6	Positive
PBS 25	24.22	1.26E+06	6.28E+04	29.6	Positive
PBS 47	24.48	1.03E+06	5.15E+04	29.8	Negative
PBS 27	25.56	4.49E+05	2.25E+04	30.9	Positive
PBS 57	26.33	2.49E+05	1.24E+04	31.7	Negative
PBS 28	26.35	2.45E+05	1.23E+04	31.7	Positive
PBS 9	27.61	9.31E+04	4.66E+03	32.9	Positive
PBS 12	28.13	6.25E+04	3.12E+03	33.5	Negative
PBS 43	28.56	4.49E+04	2.25E+03	33.9	Negative
PBS 23	29.14	2.88E+04	1.44E+03	34.5	Negative
PBS 58	29.15	2.86E+04	1.43E+03	34.5	Negative

PBS 30	29.3	2.54E+04	1.27E+03	34.6	Negative
PBS 50	29.36	2.43E+04	1.22E+03	34.7	Negative
PBS 8	29.61	2.01E+04	1.00E+03	34.9	Negative
PBS 1	30.21	1.27E+04	6.33E+02	35.5	Negative
PBS 11	30.26	1.22E+04	6.09E+02	35.6	Negative
PBS 41	30.53	9.90E+03	4.95E+02	35.8	Negative
PBS 31	30.79	8.11E+03	4.05E+02	36.1	Negative
PBS 3	30.83	7.86E+03	3.93E+02	36.1	Negative
PBS 16	31.43	4.96E+03	2.48E+02	36.7	Negative
PBS 48	31.74	3.91E+03	1.95E+02	37.1	Negative
PBS 18	31.82	3.68E+03	1.84E+02	37.1	Negative
PBS 44	31.87	3.54E+03	1.77E+02	37.2	Negative
PBS 5	32.55	2.10E+03	1.05E+02	37.9	Negative
PBS 46	32.67	1.91E+03	9.57E+01	38.0	Negative
PBS 17	32.79	1.75E+03	8.73E+01	38.1	Negative
PBS 42	33.2	1.27E+03	6.37E+01	38.5	Negative
PBS 54	33.2	1.27E+03	6.37E+01	38.5	Negative
PBS 49	33.58	9.52E+02	4.76E+01	38.9	Negative
PBS 39	33.66	8.95E+02	4.48E+01	39.0	Negative
PBS 40	33.97	7.06E+02	3.53E+01	39.3	Negative
PBS 24	34.02	6.79E+02	3.40E+01	39.3	Negative
PBS 56	34.14	6.19E+02	3.10E+01	39.4	Negative
PBS 13	34.21	5.87E+02	2.93E+01	39.5	Negative
PBS 4	36	1.49E+02	7.43E+00	41.3	Negative
PBS 20	37.73	3.94E+01	1.97E+00	43.0	Negative
PBS 6	37.97	3.27E+01	1.64E+00	43.3	Negative

Table 3. Antigen test results for available clinical specimens containing D399N and T205I nucleocapsid mutants

Specimen	Cobas 6800 C _T (E-gene)	Theoretical Roche cobas C _T	Quidel Sofia 2	Abbott BinaxNOW	Nucleocapsid Mutation	Lineage	GISAID EPI
DM1	32.58	37.9	Negative	Negative	T205I, D399N	B.1.429	EPI_ISL_1209060
DM2	21.85	27.2	Negative	Positive	T205I, D399N	B.1.429	EPI_ISL_1110097
DM3	25.48	30.8	Negative	Positive	T205I, D399N	B.1.429	EPI_ISL_1789833
DM4	20.44	25.8	Negative	Positive	T205I, D399N	B.1.429	EPI_ISL_1069365
DM5	21.72	27.1	Negative	Positive	T205I, D399N	B.1.429	EPI_ISL_1366181
DM6	23.25	28.6	Negative	Positive	T205I, D399N	B.1.429	EPI_ISL_1366195
DM7*	22.63	28.0	Negative	n.d.	T205I, D399N	B.1.429	EPI_ISL_1708574
M8	15.29	20.7	Positive	Positive	T205I	B.1.429	EPI_ISL_1405087
M9**	24.27	29.6	Positive	Negative	T205I	B.1.429	EPI_ISL_1405089
M10**	22.3	27.6	Negative	Positive	T205I	B.1.429	EPI_ISL_1405090
M11	21.21	26.6	Positive	Positive	T205I	B.1.429	EPI_ISL_1405112
M12	24.41	29.7	Positive	Positive	T205I	B.1.429	EPI_ISL_1405113
M13	22.47	27.8	Positive	Positive	T205I	B.1.429	EPI_ISL_1405115
M14	24.06	29.4	Positive	Positive	T205I	B.1.429	EPI_ISL_1405119
M15	23.4	28.7	Positive	Positive	T205I	B.1.429	EPI_ISL_1405138
M16	20.06	25.4	Positive	Positive	T205I	B.1.429	EPI_ISL_1405141
M17	22.78	28.1	Positive	Positive	T205I	B.1.429	EPI_ISL_1405148
M18	17.47	22.8	Positive	Positive	T205I	B.1.429	EPI_ISL_1405151


*Original discordant sample

**M9 and M10 were diluted to create enough volume to run on cobas 6800 for a fresh C_T (Dilution was prepared prior to both antigen and molecular testing)

n.d., not done


Table 4. Antigen testing results for detection of transiently expressed nucleocapsid proteins. The approximate initial limit of detection is highlighted in bold, where both highlighted 2/3 decisions involved a split decision on the 3rd specimen in question. The estimated amount of protein placed on a swab was calculated based on the western blot in Figure 4.

Sample	Dilution	Sofia 2	BinaxNOW	QuickVue	Estimated protein (pg)
Negative Control	1:100	0/1	0/1	0/3	
Wild-type N	1:10	3/3		3/3	560400
	1:100	3/3		3/3	56040
	1:1000	3/3	3/3	3/3	5604
	1:10000	3/3	3/3	3/3	560
	1:100000	0/3	3/3	2/3	56
	1:1000000		0/3	0/3	6
N T205I	1:10	3/3	1/1	1/1	948500
	1:100	3/3	1/1	3/3	94850
	1:1000	3/3	3/3	3/3	9485
	1:10000	3/3	3/3	3/3	948
	1:100000	0/3	2/3	3/3	95
	1:1000000		0/3	0/3	9
N D399N	1:10	6/6		3/3	673200
	1:100	1/6		3/3	67320
	1:1000	0/3	3/3	3/3	6732
	1:10000	0/3	3/3	3/3	673
	1:100000	0/3	3/3	2/3	67
	1:1000000		0/3	0/3	7
N T205I/D399N	1:10	4/4	1/1	1/1	1220800
	1:100	2/6	1/1	3/3	122100
	1:1000	0/3	3/3	3/3	12210
	1:10000	0/3	3/3	3/3	1221
	1:100000	0/3	3/3	3/3	122
	1:1000000		0/3	0/3	12

A

medRxiv preprint doi: <https://doi.org/10.1101/2021.05.05.21256527>; this version posted May 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Samples • 1 ● 10 ● 20 ● 30

**B**